Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
11.94
+0.11 (0.89%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma.
Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.
Cartesian Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 22, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Carsten Brunn |
Contact Details
Address: 7495 New Horizon Way Frederick, Maryland 21703 United States | |
| Phone | 301 348 8698 |
| Website | cartesiantherapeutics.com |
Stock Details
| Ticker Symbol | RNAC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453687 |
| CUSIP Number | 816212302 |
| ISIN Number | US8162123025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Director |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer |
| Dr. Emily English Ph.D. | SVice President and Head of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 15, 2025 | SCHEDULE 13D/A | Filing |